Nicholas Navin, PhD delivers one of the plenary lectures during the 2018 San Antonio Brest Cancer Symposium®.
The programming team for the 42nd annual San Antonio Breast Cancer Symposium® is hard at work developing a catalog of informative and engaging presentations on the latest clinical and basic research results relating to breast cancer. It recently released the preliminary program with a list of educational sessions along with the 2019 Plenary Lectures and Mini-Symposia.
“We offer these plenary lectures, mini-symposia and speakers to ensure our attendees each year have an opportunity to hear presentations on topics of pressing interest,” said SABCS® co-director Virginia Kaklamani, MD, professor of medicine, Division of Hematology/Oncology, UT Health San Antonio.
Radiation therapy for specific cancers and the tumor microenvironment will be topics of the two plenary lectures planned. Immuno-oncology in breast cancer and kinase CDK4/6 are the topics for the mini-symposia.
Ralph Weichselbaum, MD of the University of Chicago will present “Advances in Radiation Therapy for Oligometastatic Breast Cancer” for one plenary lecture. Ellen Puré, PhD of the University of Pennsylvania, Philadelphia, will present “The Tumor Microenvironment and Immunosuppression” for the other.
The mini-symposium, “Future of Immuno-oncology in Breast Cancer” will be moderated by Jenny Chang, MD of Houston Methodist Hospital and Helen Heslop, MD, DSc of Texas Children’s Hospital, Houston. Their speakers will be Elizabeth A. Mittendorf, MD, PhD of the Dana-Farber Cancer Institute at the Brigham and Women’s Cancer Center in Boston speaking on “Immunotherapy in breast cancer: enhancing response to checkpoint blockade.” Christopher A. Klebanoff, MD of Memorial Sloan Kettering Cancer Center in New York will discuss “Engineering next-gen T cell-based immunotherapies for breast cancer.”
In the other mini-symposium, Angela DeMichele, MD, MSCE of the Abramson Cancer Center at the University of Pennsylvania in Philadelphia will moderate “Targeting the Cell Cycle Kinase CDK4/6 and Beyond.” Her speakers are Sarat Chandarlapaty, MD, PhD of Memorial Sloan Kettering Cancer Center in New York discussing “Mechanisms of resistance to CDK4/6 inhibitors and new therapeutic approaches”; Rinath Jeselsohn, MD of the Dana-Farber Cancer Institute in Boston will discuss “Targeting the cell cycle — Beyond CDK4/6 inhibition.”
The 2019 SABCS will be Dec. 10-14 at the Henry B. Gonzalez Convention Center. Registration, hotel reservations, and the call for abstracts are currently open.